Immunosuppression Under Trial

Part 1 Setting the stages in clinical trials: Current results as reference for future improvements in immunosuppression, G. Opelz, et al; Rationale of clinical trials from the physician, C. Legendre; Minimal standards for reporting clinical trial results in transplantation, B.L. Kasiske, H. Chakkera; Methodological approach of clinical trials for renal transplantation, P. Landais, J.P. Jais. Part 2 Is acute rejection an appropriate surrogate marker?: Surrogate endpoints for clinical trials in renal transplantation, B.L. Kasiske; Is acute rejection an appropriate surrogate marker for clinical trials in liver transplantation? O. Farges; The success of clinical immunosuppressive trials in heart transplantation - the early detection of acute rejection, M. Antoine. Part 3 Towards long-term end-points: Factors influencing long-term allograft survival, C. Van Buren. Part 4 Can we minimize the long-term side-effects?: Patients' appraisal of side-effects in quality of life assessments of immunosuppressive regimens, P. Moons, et al; Cardiovascular complications after renal transplantation, V. Schwenger, et al; Strategies to minimize nephrotoxicity associated with calcineurin inhibitors, J. Alsina; Diabetogenic effect of immunosuppressive drugs, X. Martin; Can we minimize long-term side effects of immunosuppressive drugs on lipid metabolism? Z.A. Massy; Can we minimize the long-term side-effects of immunosuppressive drugs in pediatric patients? B. Tonshoff, et al. Part 5 Strategies: Induction therapy, D. Abramowicz, K.M. Wissing; Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence - randomised comparison of two cyclosporin regimens, J. Dantal, et al; Immunosuppression in composite tissue transplantation, J.-M. Dubernard, et al; The search for immunosuppressive synergy, C. Van Buren; Economic analysis of immunosuppression in transplantation - a review of recent studies in liver and kidney transplantation, J. Hutton. Part 6 Clinical trials for at-risk situations; Questions raised by the exclusion of "at risk" conditions from current trials in organ transplantation, J.P. Revillard, et al.